Lumos Diagnostics Holdings Limited (LDXHF)

Market Cap	46.98M -47.3%
Revenue (ttm)	13.19M +6.4%
Net Income	-4.95M
EPS	-0.01
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	50,000
Open	0.0500
Previous Close	0.0400
Day's Range	0.0500 - 0.0500
52-Week Range	0.0400 - 0.2400
Beta	0.46
Analysts	n/a
Price Target	n/a
Earnings Date	Oct 27, 2026

About LDXHF

Lumos Diagnostics Holdings Limited develops, manufactures, and distributes diagnostic technologies in the United States. The company offers FebriDx, a point-of-care diagnostic test for acute respiratory infections, and ViraDx, a three-in-one point-of-care test for influenza A, influenza B, and COVID-19. It also provides assay development and manufacturing services for point-of-care tests and proprietary digital reader platforms. The company was incorporated in 2018 and is headquartered in Carlsbad, California.

• Industry: Medical Devices
• Sector: Healthcare
• Founded: 2018
• Country: Australia
• Stock Exchange: OTCMKTS
• Ticker Symbol: LDXHF

Financial Performance

In fiscal year 2026, LDXHF's revenue was $13.19 million, an increase of 6.39% compared to the previous year's $12.40 million. Losses were -$4.95 million, -31.06% less than in 2025.

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Nov 9, 2026

Data Sources Report a data error